Q-omics provides the consensus-scored CPO profile across patient tissues and cancer cell-line models. CPO expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CPO is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CPO RNA expression shows 16,524 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KICH, and UVM as cancer lineages where CPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPO survival associations across molecular data types. CPO RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPO RNA expression–survival associations across cancer types. High CPO expression shows favorable associations in MESO, KIRP, ACC, HNSC, SARC and PCPG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CPO RNA expression.
This table summarizes CPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPO shows lower tumor expression in KICH, THCA, BLCA, LUSC, KIRP and UCEC. The KICH box plot shows higher CPO RNA expression in normal versus tumor tissue (log2 FC = −1.008, t-test p < 0.001).
This table shows molecular features associated with CPO in patient tissues and cancer cell lines. In patient samples, CPO shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
